Preclinical studies have demonstrated that VX-765 administration effectively reduces IL-1β secretion and attenuates inflammation in models of inflammatory diseases and alleviates DSS-induced colitis in mice by suppressing caspase-1 mediated pyroptosis [163,183,184]. Here, IL1B is linked to colitis.